Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases Patients affected by severe genetic and orphan diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND ORPHAN DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

events

spotlight

January 29, 2015

bluebird bio Announces Transition of Chief Scientific Officer

Read More

January 6, 2015

bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Read More

December 15, 2014

bluebird bio Announces Pricing of Public Offering of Common Stock

Read More

December 15, 2014

bluebird bio Announces Proposed Public Offering of Common Stock

Read More